Wilbur A. Franklin

Wilbur A. Franklin's AcademicInfluence.com Rankings

Wilbur A. Franklin

Medical

#3240

World Rank

#3698

Historical Rank

Oncology

#225

World Rank

#233

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Wilbur A. Franklin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wilbur A. Franklin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) (3193)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. (2005) (1575)
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. (2003) (1402)
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. (2014) (1364)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer (2012) (1030)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. (2006) (736)
Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior (2010) (688)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. (2008) (603)
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. (2009) (594)
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. (2005) (589)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. (2006) (504)
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. (2001) (390)
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. (2006) (378)
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. (2005) (371)
Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. (2013) (368)
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment (2010) (328)
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. (1997) (326)
Sequence variants at CHRNB 3 – CHRNA 6 and CYP 2 A 6 affect smoking behavior (2010) (312)
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. (2008) (300)
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience (2015) (297)
High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. (2002) (294)
A major lung cancer susceptibility locus maps to chromosome 6q23-25. (2004) (292)
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. (2006) (289)
Epidermal growth factor receptor family in lung cancer and premalignancy. (2002) (288)
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. (2005) (284)
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. (2008) (268)
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. (2005) (263)
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. (2005) (255)
The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. (2002) (254)
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. (2008) (247)
Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer (2012) (242)
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed (2011) (230)
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas (2002) (220)
Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. (1996) (218)
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. (2009) (218)
The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. (2008) (205)
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. (2003) (204)
The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (197)
Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. (2010) (197)
Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. (2001) (194)
Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer (2010) (194)
Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. (2000) (190)
Morphology in Ki‐1 (CD30)‐Positive Non Hodgkin's Lymphoma Is Correlated with Clinical Features and the Presence of a Unique Chromosomal Abnormality, t(2;5)(p23;q35) (1990) (188)
Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer (2012) (177)
WNT7a induces E-cadherin in lung cancer cells (2003) (177)
The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. (1989) (176)
PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers (1998) (176)
Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. (2002) (155)
The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification (2016) (152)
Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. (1996) (151)
Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. (2013) (150)
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. (2006) (149)
Altered HOX and WNT7A expression in human lung cancer. (2000) (148)
Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non–Small Cell Lung Cancer Patients (2017) (144)
Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. (2001) (142)
Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines (2006) (142)
Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria (2006) (140)
Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. (2002) (136)
Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. (2000) (133)
Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma (2005) (133)
Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast (1987) (128)
Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels (2006) (127)
Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. (1998) (126)
Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (126)
Pulmonary Prostacyclin Synthase Overexpression Chemoprevents Tobacco Smoke Lung Carcinogenesis in Mice (2004) (118)
Adenosine A2A receptor is a unique angiogenic target of HIF-2α in pulmonary endothelial cells (2009) (117)
New anti‐lung‐cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma (1994) (113)
KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. (2010) (113)
γ-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth (2002) (106)
HER2/neu expression in malignant lung tumors. (2002) (106)
Modulation and function of intercellular adhesion molecule-1 (CD54) on human retinal pigment epithelial cells. (1992) (105)
Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. (1996) (105)
The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification (2009) (104)
Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer (2006) (103)
Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. (1997) (102)
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium (2015) (101)
Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia. (2000) (101)
Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum (2007) (101)
The folate-binding protein of rat kidney. Purification, properties, and cellular distribution. (1984) (100)
High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation (2012) (98)
Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers (2011) (98)
Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. (1996) (97)
Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. (2008) (97)
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. (2008) (95)
Defining a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment (2012) (94)
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. (2006) (94)
Homozygous deletions of human chromosome 3p in lung tumors. (1997) (92)
Comparative analysis of algorithms for signal quantitation from oligonucleotide microarrays (2004) (91)
The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases (2006) (90)
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. (2009) (89)
Proteomic patterns of preinvasive bronchial lesions. (2005) (87)
The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer (2016) (81)
Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer (2013) (81)
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients (2005) (80)
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. (2011) (80)
Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. (2003) (80)
Maturation-related changes in endothelial nitric oxide synthase immunolocalization in developing ovine lung. (1994) (79)
EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer (2007) (77)
Endotoxin induces cardiac HSP70 and resistance to endotoxemic myocardial depression in rats. (1996) (76)
Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. (2010) (74)
Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. (2003) (72)
Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease (2017) (71)
Analysis of c-ErbB1/Epidermal Growth Factor Receptor and c-ErbB2/HER-2 Expression in Bronchial Dysplasia: Evaluation of Potential Targets for Chemoprevention of Lung Cancer (2006) (71)
Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. (2004) (70)
A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). (2013) (68)
Validation of a blood protein signature for non-small cell lung cancer (2014) (68)
Molecular classification and molecular genetics of human lung cancers. (2004) (68)
Lung cancer diagnosis from proteomic analysis of preinvasive lesions. (2011) (68)
Role of biomarkers for early detection of lung cancer and chemoprevention (2002) (65)
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. (2010) (65)
Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy (2006) (64)
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. (2005) (63)
Epidermal growth factor receptor immunohistochemistry (2008) (62)
Giant lymph node hyperplasia with osteoblastic bone lesions and the POEMS (takatsuki's) syndrome (1985) (62)
Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. (2016) (62)
Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma (2012) (60)
Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. (1990) (60)
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. (2000) (60)
Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) (2006) (60)
Correlation of PD‐L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early‐Stage Squamous Cell Lung Carcinoma (2019) (60)
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort (2009) (58)
Absence of p53 mutations in squamous carcinomas of the tongue in nonsmoking and nondrinking patients younger than 40 years. (1997) (58)
A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer (2012) (55)
The Detection of Chromosomal Aneusomy by Fluorescence In situ Hybridization in Sputum Predicts Lung Cancer Incidence (2010) (52)
Papillomavirus found in anorectal squamous carcinoma, not in colon adenocarcinoma. (1992) (51)
Chemoprevention of lung cancer--from biology to clinical reality. (2004) (51)
Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. (2004) (51)
Induction of a high incidence of lung tumors in C57BL/6 mice with multiple ethyl carbamate injections. (2003) (50)
Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. (1999) (49)
Tissue binding of lectins in disorders of the breast (1983) (49)
Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses (1992) (48)
Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. (2006) (48)
Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer (2011) (48)
Chromosomal duplication accompanies allelic loss in non-small cell lung carcinoma. (1998) (47)
Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer (2013) (47)
Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. (2006) (46)
Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the microTICAS image analysis system. (1987) (45)
Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. (2011) (45)
Bronchioloalveolar Carcinoma (2004) (44)
Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis. (2005) (43)
Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 (2008) (41)
Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present (2004) (41)
Deletion of the p53 gene in a patient with aggressive burn scar carcinoma. (1997) (40)
Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. (2008) (39)
Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib (2005) (37)
CD68 antigen expression by human retinal pigment epithelial cells. (1992) (36)
In Situ Distribution of the β-Subunit of Platelet-derived Growth Factor Receptor in Nonneoplastic Tissue and in Soft Tissue Tumors (1990) (35)
Sputum Cytologic Atypia Predicts Incident Lung Cancer: Defining Latency and Histologic Specificity (2008) (35)
Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. (2005) (34)
Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer (2009) (34)
Finding ALK-positive lung cancer: what are we really looking for? (2011) (33)
Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer. (2007) (33)
KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer (2009) (33)
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. (2010) (32)
Ethidium bromide: a nucleic acid stain for tissue section. (1981) (31)
Bronchial Epithelial Ki-67 Index Is Related to Histology, Smoking, and Gender, but Not Lung Cancer or Chronic Obstructive Pulmonary Disease (2007) (31)
S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. (2009) (31)
Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention (1997) (31)
Assessment of hormone receptors in breast carcinoma by immunocytochemistry and image analysis. II. Estrogen receptors. (1989) (31)
In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit. (1990) (29)
High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. (2005) (29)
Molecular Pathology of Non-Small Cell Lung Cancer. (2012) (27)
Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma (2015) (26)
KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. (2009) (26)
High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts) (2007) (26)
A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without α Tocopherol or Observation in Subjects at High Risk for Lung Cancer (2009) (26)
Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung (2017) (26)
A rare missense mutation in CHRNA4 associates with smoking behavior and its consequences (2016) (26)
Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). (2004) (25)
Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. (2006) (25)
Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk. (2011) (25)
Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. (2004) (24)
ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). (2010) (24)
Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126) (2005) (23)
Glomerulonephritis associated with male pseudohermaphroditism and nephroblastoma (1983) (23)
In situ distribution of the beta-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. (1990) (22)
Application of SNP Microarrays to the Genome-Wide Analysis of Chromosomal Instability in Premalignant Airway Lesions (2013) (21)
A randomized study of fluorescence bronchoscopy versus white-light bronchoscopy for early detection of lung cancer in high risk patients (2000) (21)
Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites. (1996) (21)
Immunofluorescence localization of thyroglobulin in metastatic thyroid cancer (1982) (20)
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. (2002) (20)
Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support (1996) (20)
Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. (2012) (19)
Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): Preliminary results of the ONCOBELL trial. (2006) (19)
Immunophenotype of small cell lung carcinoma: Expression of NKH‐1 and transferrin receptor and absence of most myeloid antigens (1988) (18)
Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. (2018) (18)
Pathology of lung cancer. (2000) (18)
Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention (2012) (17)
Modulation of the expression of major histocompatibility antigens on splenic hairy cells--differential effect upon in vitro treatment with alpha-2b-interferon, gamma-interferon, and interleukin-2. (1988) (17)
One-step duplex reverse transcription-polymerase chain reaction for quantitative assessment of RNA degradation. (2001) (17)
An (8;14)(q24;q11) translocation involving the T‐cell receptor α‐chain gene and the MYC oncogene 3′ region in a B‐cell lymphoma (1989) (16)
Molecular staging and pharmacogenomics. Clinical implications: from lab to patients and back. (2003) (16)
Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature. (2016) (16)
Prostacyclin in human non-small cell lung cancers. (2004) (16)
Functional Genomics of Lung Disease (2004) (15)
Differentiation and programmed cell death-related intermediate biomarkers for the development of non-small cell lung cancer: a pilot study. (1998) (15)
IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. (2002) (15)
Carcinoid tumor of the pancreas causing the diarrheogenic syndrome: report of a case combined with multiple endocrine neoplasia, type I. (1986) (14)
Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer. (2009) (14)
Expression of target molecules in lung cancer: challenge for a new treatment paradigm. (2002) (14)
Bone marrow involvement by lobular carcinoma of the breast cannot be identified reliably by routine histological examination alone. (1994) (14)
In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions. (2002) (14)
Low neutral endopeptidase levels in bronchoalveolar lavage fluid of lung cancer patients. (1999) (14)
Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance). (2020) (13)
Evaluation of HER2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH) (2000) (13)
Premalignant evolution of lung cancer: Gilles F Filley lecture. (2004) (13)
What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? (2002) (13)
EU–USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer (2006) (13)
Estrogen and progesterone receptors in endodermal sinus (yolk sac) tumor. Evaluation of immunocytochemical and biochemical methods. (1989) (12)
Mutational inactivation of aminoacylase‐1 in a small cell lung cancer cell line (1998) (12)
O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment (2005) (12)
O-187 ZD1839 (iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG SO126 (2003) (12)
Nuclear Accumulation of β-Catenin Occurs Commonly in the Epithelial Cells of Juvenile Polyps (2005) (12)
High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum. (2004) (11)
Carboxypeptidase M. Variable expression in normal human lung and inactivation in lung cancer. (1997) (11)
A Comparison of Survival and Disease‐Specific Survival in Surgically Resected, Lymph Node‐Positive Bronchioloalveolar Carcinoma Versus Nonsmall Cell Lung Cancer: Implications for Adjuvant Therapy (2008) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. (2013) (11)
Is there a direct differentiation‐inducing effect of human recombinant interferon on hairy cell leukemia in vitro? (1989) (10)
C225 anti-epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo (2001) (10)
A histopathologic evaluation of premalignant and early malignant bronchial lesions: An interactive program based on internet digital images to improve WHO criteria for early diagnosis of lung cancer and for monitoring chemoprevention studies—A SPORE collaborative project (2000) (10)
Neural cell adhesion molecule expression in human pituitary adenomas (2005) (10)
Molecular events in lung carcinogenesis. (1997) (10)
First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. (2008) (10)
Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit. (2016) (10)
Examination of p53 alterations and cytokeratin expression in sputa collected from patients prior to histological diagnosis of squamous cell carcinoma (1996) (10)
Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. (2013) (10)
Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341) (2007) (10)
ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. (2012) (9)
Prognostic patterns in the histopathology of pulmonary adenocarcinoma. (2012) (9)
Molecular and physiologic evidence for 5'CpG island methylation of the endothelin B receptor gene in lung cancer. (2002) (9)
RAGE in lung tumors. (2007) (9)
The evolution of tumor classification: a role for genomics? (2013) (9)
Macula densa cells of mouse kidney do not synthesize epidermal growth factor precursor mRNA. (1990) (8)
CD19 selection improves the sensitivity of B cell lymphoma detection. (1998) (8)
Assessment of hormone receptors in breast carcinoma by immunocytochemistry and image analysis. I. Progesterone receptors. (1989) (8)
Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer (2017) (8)
The biology of bronchial premalignancy (1996) (7)
EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. (2007) (7)
Dramatic response to pemetrexed in a patient with pneumonic-type mucinous bronchioloalveolar carcinoma. (2011) (7)
Biomarkers are here to stay for clinical research and standard care. (2010) (6)
Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with non-small cell lung cancer. (2019) (6)
Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays. (2004) (6)
O-296 Aberrant DNA methylation and sputum atypia predict lung cancer — Preliminary report from the University of Colorado SPORE high risk cohort study (2003) (6)
The aryl hydrocarbon receptor repressor (2008) (5)
Long-term survival with gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126 (2008) (5)
Chronic persistent cough in the adult. (1981) (5)
Sarcomas arising after radiotherapy for peptic ulcer disease (1985) (5)
Overcoming resistance to EGFR inhibitors in NSCLC cell lines by sequential treatment with histone deacetylase inhibitors (2005) (5)
Characterization of antibody-forming cells adjacent to laryngeal carcinoma. (1984) (5)
SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). (2009) (5)
Inactivation of neutral endopeptidase in lung cancer. (1996) (5)
Retroperitoneal Paraganglioma in a Tiger (Panthera tigris) (1988) (4)
Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: Implications for ALK inhibitor therapy. (2012) (4)
Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC) (2007) (4)
Adjusting interphase FISH results in epithelial tissue sections to whole cell complement. (2001) (4)
PD3-1-7: Phase II trial of autologous cancer vaccine, CG8123 (GVAX), in patients with advanced bronchioloalveolar carcinoma (BAC): a Southwest Oncology Group Study (S0310). (2007) (4)
26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies (2006) (4)
574 Evidence for an endothelin-1 autocrine loop in lung cancer (1997) (4)
EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib. (2006) (3)
Kinetics of a novel cytosolic protein during the onset of renal epithelial cell growth. (1988) (3)
Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC). (2013) (3)
676 CD34 expression on pediatric solid tumors (1996) (3)
Correlative assessment of morphologic, immunophenotypic, and genetic changes in bronchial epithelium of tobacco smokers. (1996) (3)
Magnetic resonance imaging and intravenous infusion devices. (1986) (3)
P-272 Angiogenic squamous dysplasia (ASD): A biomarker highly associated with squamous cell lung carcinoma (2003) (3)
Lack of Association between Sputum Atypia and Chronic Obstructive Pulmonary Disease Mortality (2006) (2)
D4-02: Aneusomy by FISH analysis and histology as predictors of invasive lung cancer in bronchial biopsies from high risk subjects (2007) (2)
Erratum: High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation (Journal of Thoracic Oncology (2012) 7 (520-527)) (2012) (2)
Immunohistochemical detection of antibody in tissue sections of non-perfused and ex vivo-perfused organs using a tetrazolium alkaline phosphatase substrate (2004) (2)
Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience. (2014) (2)
Oral Iloprost For The Chemoprevention Of Lung Cancer (2010) (2)
P-305 Mutant DNA in Southwest Oncology Group (SWOG) S0003 non-small cell lung cancer (NSCLC) patient plasma: Potential for monitoring response to therapy (2003) (2)
SWOG Cooperative Group Biorepository Resource: Access for Scientific Research Studies (2011) (2)
Pathology, Biomarkers, and Molecular Diagnostics (2020) (2)
675 Micropapillary squamous metaplasia: A lesion reflecting angiogenesis in bronchial mucosa of smokers☆ (1997) (1)
Epidermal growth factor receptor (EGFR) gene amplification in non-small cell lung cancer (NSCLC): molecular patterns and sensitivity to tyrosine kinase inhibitors: A5-01 (2007) (1)
Somatic mutation in the EGFR gene in ovarian carcinoma detected by SSCP and direct sequencing. (2006) (1)
Lung cancer: Premalignant biology and medical prevention. (2022) (1)
Persistence of angiogenic squamous dysplasia for a year or more at the same bronchial sites in individuals at high risk for lung cancer (2000) (1)
P1.05-001 Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium: Topic: Translational Research and Biomarkers (2017) (1)
P3.01-021 Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumor Nodules: Topic: Morphology (2017) (1)
547 Complex abnormalities involving chromosomal regions 3p and 9p in non-small cell lung cancer (NSCLC) revealed by fluorescence in situ hybridization (FISH) (1997) (1)
Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients. (2011) (1)
P53 mutation is associated with multiple copies of mutant p53 allele and with chromosomal instability in non-small cell lung carcinoma (NSCLC) (2000) (1)
Optimizing peptide epitope-based autoantibody detection in cancer patients. (2017) (1)
Sputum dysplasia, related to bacterial load, oxidative stress, and airway inflammation in COPD. (2004) (1)
Chromosomal aneusomy in sputum predicts for lung cancer in nested case-control study. (2006) (1)
P-616 EGFR expression in non-small-cell lung cancer: interobserver reproducibility of visually interpreted EGFR immunohistochemical staining (2003) (1)
Biomarker Discovery and Verification of a Lung Cancer Signature with SOMAmer Proteomic Technology (2012) (1)
Predictive Biomarkers and Personalized Medicine Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non – Small Cell Lung Cancer (2012) (1)
Antigen-presenting tumor B cells impact the phenotype of CD4 tumor infiltrating T cells in lung cancer patients (2017) (1)
Correlation of thymidylate synthase genotype and protein expression and association with lung cancer survival. (2011) (1)
A Nucleic Acid Stain for Tissue Sections (1981) (1)
Analysis of c-erb-1 (EGFR) and c-erb-2 (HER2) expression in bronchial dysplasia: Evaluation of potential targets for chemoprevention of lung cancer. (2006) (1)
O-191 HER1-HER2-HER3 gene amplification and akt activation inpatients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib (2005) (1)
O-131 High prevalence of endobronchial malignancy in high-risk patients who have moderate dysplasia in sputum (2003) (1)
Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation (2022) (1)
FISHing for lung cancer: Promising findings using multi-targeted interphase fluorescence in situ hybridization (FISH) for lung cancer detection in sputum (2007) (1)
Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity. (2016) (1)
Prognostic significance of EGFR FISH and IHC in non small-cell lung cancer patients treated with chemotherapy alone. (2006) (1)
Expression of neutral endopeptidase is reduced in lung cancer (1994) (1)
Airway antioxidants and oxidative stress as predictors of sputum atypia and airflow obstruction. (2004) (0)
P3-146: Sensitive PCR method detects EGFR exon19 deletions in NSCLC (2007) (0)
P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma (2018) (0)
O-135 WNT7a induces E-cadherin in lung cancer (2003) (0)
O-049 Affymetrix gene expression profiles in premalignant bronchialmucosa (2005) (0)
Defining the association of methylation biomarkers for establishing lung cancer risk: A nested case-control study of a high-risk cohort (2003) (0)
Evaluation of chromosomal aneusomy in bronchial epithelium of smokers as a marker for lung cancer risk (2004) (0)
768 Incidence of advanced dysplasia and carcinoma in situ in white-light-directed biopsies at normal appearing endobronchial sites is higher than expected in patients with increased risk of lung cancer (1997) (0)
783 New EGFR variants around the EGFRvIII region in non-small cell lung cancers(NSCLC) (2003) (0)
Molecular and Cell Biology of Lung Carcinoma (2004) (0)
P2.03-019 Sizing Capillary Electrophoresis with PCR to Detect Various EGFR Exon 19 Deletions in Non-Small Cell Lung Cancer (2017) (0)
PD-057 Increased expression of C-erb-B1 (EGF-R) but not C-erb-B2 (HER2) is associated with dysplastic change in bronchial airways: Correlation with increased 1,067, MCM2 and P53 expression (2005) (0)
P-273 The role of Ki67, p53, EGFR, HER2 and CD31 as possible predictive biomarkers for development of lung cancer in a high-risk population (2003) (0)
PD2-2-6: Angiogenesis in bronchial dysplasia and angiogenic squamous dysplasia is associated with the development of immature vasculature (2007) (0)
BLOOD REPOSITORY FOR THE VALIDATION OF LUNG CANCER BIOMARKERS LUNG CANCER BIOMARKERS GROUP (2007) (0)
Performance of Cancer/Testis Antigens and EEF1A2 mRNAs measured by qRT‐PCR as tissue biomarkers for NSCLC (2008) (0)
AntitumorActivityof the EpidermalGrowth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non^Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFRMutations but not EGFRProtein Levels (2006) (0)
P1.02-084 Polo-Like Kinase 1 (PLK1) Inhibition Decreases Mutational Activity in Bronchial Epithelial Cells Exposed to Tobacco Carcinogens: Topic: Other Mutations in Thoracic Malignancies (2017) (0)
Chapter 10 Limited expression of myeloid antigens by neuroendocrine tumours of lung (1988) (0)
Abstract A55: Mapping the airways: The fate of bronchial epithelium in long term heavy smokers (2015) (0)
Identification of alterations in gene expression that distinguish persistent from regressive bronchial dysplasia (2011) (0)
Abstract 231: Gene expression analysis of persistent and regressive bronchial dysplasia identifies polo-like kinase 1 (PLK1) and epoxide hydrolase 3 (EPHX3) as potential mediators of malignant progression (2014) (0)
Molecular biomarkers for early detection of lung cancers (2004) (0)
A numerically fit model equation for adjusting fluorescence in situ hybridization signal counts in tissue sections to in vivo ploidy for epithelial cells (2000) (0)
Detection of chromosome 3 abnormalities in cytospin and touch preparations of lung tumors using fluorescence in situ hybridization (1996) (0)
Abstract LB-90: Oral iloprost improves endobronchial dysplasia in former smokers (2011) (0)
P2.06-032 Oral Pioglitazone for the Chemoprevention of Lung Cancer in Current and Former Smokers: Topic: Supportive, Preventive (2017) (0)
P-274 Application of nested RT-PCR assay for detection of MAGE-A3-positive lung cancer cells in sputum (2003) (0)
Analysis ofDNAPloidy andProliferative Activity inRelation toHistology andN-myc Amplification inNeuroblastoma (1990) (0)
Chromosome 3 abnormalities in lung tumors detected by fluorescence in situ hybridization (1997) (0)
Inflammation and lung cancer: Molecular pathology (2015) (0)
Abstract 2727: Predicting lung cancer risk based on a novel proteomic signature of bronchial lesions (2010) (0)
601 Association of the angiotensin-converting enzyme (ACE) ID polymorphism with susceptibility to lung cancer (1997) (0)
Abstract 4550: Correlations between tumor mutation burden, inflammatory profile and histological characteristics of tumor microenvironment in early-stage squamous cell lung carcinoma (2019) (0)
Outcomes in bronchial dysplasia: persistence of lesions and associations with development of invasive non-small cell lung cancer: A7-05 (2007) (0)
P-679 EU-US pathologypanel for uniform diagnosis in randomised controlled trials for ct screening of lung cancer. Learning phase in diagnosis of early lung cancer (2005) (0)
724 Low neutral endopeptidase/protein ratio is found in the bronchoalveolar lavage of patients with carcinoma of the lung (1997) (0)
The Pathology and Pathogenesis of Peripheral Lung Adenocarcinoma Including Bronchioloalveolar Carcinoma (2008) (0)
P-306 Molecular abnormalities in anti-microtubule and DNA damage response pathways in non-small cell lung carcinomas (NSCLC): Southwest Oncology Group (SWOG) 9509 trial (2003) (0)
OA19.01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium (2017) (0)
Update on the use of oral iloprost for the chemoprevention of lung cancer: A7-04 (2007) (0)
E-27. Overview: Impact of microarray technology on lung cancer classification and biomarker development (2003) (0)
Validation of a blood protein signature for non-small cell lung cancer (2014) (0)
Bronchial epithelial proliferation measured by Ki-67 is related to current smoking and sex but not to lung cancer or chronic obstructive pulmonary disease: P1-192 (2007) (0)
NEW MOLECULAR AND CELLULAR APPROACHES TO LUNG CANCER DETECTION (1998) (0)
Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations (2013) (0)
Human Cancer Biology Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma (2012) (0)
Defining a FISH chromosomal aneusomy panel for predicting lung cancer in the setting of CT-detected lung nodules. (2012) (0)
P-265 Natural history of untreated endobronchial carcinoma in situ (2005) (0)
New molecular and cellular approaches to early detection of lung cancer (2003) (0)
Abstract PL04-02: Oral iloprost for the chemoprevention of lung cancer: A multicenter, SPORE-initiated trial (2011) (0)
Insulin-like growth factor receptor 1 (IGFR-1) is signiﬁcantly associated with longer survival in non-small-cell lung cancer patients treated with geﬁtinib (2006) (0)
EGFR Amplification in Lung Cancer: Time for Thawing the Frozen FISH? (2016) (0)
594 Expansion of bronchial epithelial cell populations from bronchoscopic biopsies and thoracotomy specimens by one step transfection of cultured cells with SV-40 T antigen (1997) (0)
P1.05-027 Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium: Topic: Translational Research and Biomarkers (2017) (0)
Abstract 4121: Folate pathway in malignant pleural mesothelioma (MPM): Novel therapeutic opportunities due to folate receptor alpha overexpression (2011) (0)
P2-047: Putative biomarker genes for pemetrexed theatment in small and non-small cell lung cancer cell lines, detected by microarray analysis (2007) (0)
Abstract 2356: Biomarkers of progressive squamous lung dyplasia. (2013) (0)
P-264 Ki67 proliferation index in endobronchial biopsies: Associationwith lung cancer, airflow obstruction and smoking history (2005) (0)
Abstract PR04: Distinctive squamous cell carcinoma protein signatures. (2014) (0)
Molecular events in lung carcinogenesis : Multidisciplinary care of lung cancer patients, Part I (1997) (0)
3002 ORAL Comprehensive assessment of molecular markers predicting response to cetuximab therapy in colorectal cancer (2007) (0)
Surprised by stage III: unexpected N2 lymph node involvement found during surgery for early-stage NSCLC. (2009) (0)
Preliminary results from a phase II trial evaluating 13 cis-retinoic acid with or without alpha tocopherol or observation in patients at high risk for lung cancer (2000) (0)
Abstract ED01-03: Chemoprevention of lung cancer with prostacyclins or PPAR gamma agonists. (2011) (0)
O-301 Prostacyclin in human non-small cell lung cancers and regulatory mechanisms (2003) (0)
PCR method for detection of EGFR exon 19 deletion in NSCLC (2007) (0)
Erratum: (The Journal of Clinical Investigation (October 1997) 100:8 (2133-2137)) (1997) (0)
Epidermal Growth Factor Receptor Messenger RNAExpression , Gene Dosage , and Gefitinib Sensitivity in Non ^ Small Cell Lung Cancer (2006) (0)
Characteristics of NSCLCs harboring NRAS mutations. (2012) (0)
P3.03-25 Squamous Cell Carcinoma-Associated Bronchial Dysplasias Demonstrate Altered T-helper Lymphocyte Differentiation (2018) (0)
PD-056 Clinical update on the phase II trial of oral iloprost in the chemoprevention of lung cancer in high risk patients (2005) (0)
Antimicrotubule-Platinum Therapy in NSCLS by Histologic Subtypes 628-Introduction (0)
A Textbook of Clinical Pathology (1961) (0)
Assessment of microRNA regulation of INCENP, KRT14, and KRT16 in lung cancer (2008) (0)
Molecular and Cellular Changes During Multistep Carcinogenesis in the Lung (2002) (0)
MTP2-01: Bronchioloalveolar carcinoma (2007) (0)
Tissue sampling and digital histologic imaging for the National Lung Screening Trial. (2010) (0)
Molecular Testing Is a Valuable Adjunct for Distinguishing Second Primary Tumors of Lung From Intrapulmonary and Extrapulmonary Metastases (2015) (0)
MA01.02 Non-Invasive LuCED® Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with Drugs Such as Iloprost (2017) (0)
460 Proteomic Insights in Oncology: What Have We Learned From Measuring Millions of Proteins? (2012) (0)
O-76 Oligonucleotide microarray gene expression profiles of lung cancer cell lines sensitive and resistant to ZD-1839 (2003) (0)
PP117 Increased EGFR gene copy number is variably associated with both EGFR and KRAS Mutation (Mt) status and influences Progression Free Survival (PFS) to first-line chemotherapy in EGFR/KRAS wildtype (WT) patients (2009) (0)
Defining Best Practices for Determining KRAS Mutations in Colon Cancer (0)
Abstract B19: Malfunction and mutation of airway stem/progenitor cells in preneoplastic bronchial dysplasia (2015) (0)
MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma (2017) (0)
Abstract 1675: Variations in the composition of inflammatory infiltrates are associated with persistence or regression of bronchial dysplasia (2014) (0)
P-277 A histological model to predict airway response to promising chemoprevention agents in phase II lung cancer prevention trials (2003) (0)
Evaluation of chromosomal aneusomy in bronchial epithelium of smokers as a marker for lung cancer risk. (2004) (0)
Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events (2010) (0)
Nonlymphoblastic T‐cell lymphoma in children (1987) (0)
High affinity folate binding protein (FBP) in the basolateral membrane of retinal pigment (RPE) and ciliary body pigment (CBPE) epithelia (1985) (0)
P-245 245 Detection of RNA biomarkers in sputum of lung cancer patientsand high risk smokers (2005) (0)
Methods for predicting clinical outcome for inhibitors of epidermal growth factor receptor for cancer patients (2005) (0)
Detection of chromosome deletions in direct tumor preparations using fluorescence in situ hybridization (1997) (0)
Gene predictors for extrathoracic metastases (EM) in advanced bronchioloalveolar carcinoma (BAC) of the lung obtained from formalin-fixed, paraffin-embedded tissue (FFPE) (2007) (0)
Abstract 1492: Histological and molecular characteristics of 29 cases of carcinomain situfrom a prospective bronchoscopic cohort (2010) (0)
Abstract B16: Histology and intervention related miRNA expression changes from baseline to follow-up paired bronchial biopsies of patient in the iloprost chemoprevention trial (2012) (0)
MUC1 alternative mRNA splice variants in lung cancer (2000) (0)
P2.09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma (2018) (0)
S4-4 Integration of Correlative Science into Clinical trial Design in Lung Cancer (2004) (0)
Survival benefit of gefitinib treated non-small-cell lung cancer patients with exon 19 deletion mutations in epidermal growth factor receptor (EGFR), detected by a new sensitive PCR-based method (2007) (0)
ning a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment (2012) (0)
Assessing lung cancer risk in bronchial dysplasia by identification of prognostic gene expression profiles (2010) (0)
Epidermal G rowth F actor R eceptor i n N on-Small-Cell L ung Carcinomas: C orrelation B etween G ene C opy N umber a nd Protein E xpression a nd I mpact o n P rognosis (2003) (0)
Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC. (2012) (0)
Angiogenesis in bronchial dysplasia and angiogenic squamous dysplasia is associated with the development of immature vasculature: PD2-2-6 (2007) (0)
P-269 Angiogenic activity in bronchial dysplasia and invasive lung cancer: Features of vascular endothelial growth factor (VEGF) expression (2003) (0)
P-331 Chromosomal instability detected by SKY FISH is common in bronchial cells of high-risk smokers (2003) (0)
Title : Antigen-presenting intratumoral B cells affect CD 4 + TIL phenotypes in non-small cell lung cancer patients (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wilbur A. Franklin?

Wilbur A. Franklin is affiliated with the following schools:

Wilbur A. Franklin's Academic­Influence.com Rankings

Why Is Wilbur A. Franklin Influential?

Wilbur A. Franklin's Published Works

Published Works

What Schools Are Affiliated With Wilbur A. Franklin?

Wilbur A. Franklin's AcademicInfluence.com Rankings